Nat Med: CXCR4 Antagonists , PD-1 inhibitors , chemotherapy triple therapy for pancreatic cancer breakthrough
-
Last Update: 2020-06-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Data from the clinical trial COMBAT (KEYNOTE-202), recently released byof, show that the new CXCR4 inhibitor BL-8040 (Motixafortide), in combination with PD-1 inhibitors and chemotherapy, has initially performed well in second-line/third-line treatment spree for pancreatic cancerPrevious report: BioLineRx announces..This information is only open to readMetz Medical APP, please scan the QR code to download the app
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.